epidemiology and risk factors for IFI is important in identifying subsets of BMT recipients for clinical trials investigating the effects of novel preventive measures, as In order to analyze the incidence and risk factors for invasive fungal infection (IFI) after allogeneic BMT, 142 well as clinical decision-making on the management of patients after allogeneic BMT. consecutive adult BMT recipients (131 sibling donors, 11 unrelated donors) transplanted in 1989-1993 were
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Diagnosis of invasive fungal infections
Mtx-CsA 74 (52) Mtx-CsA-MP 68
The diagnosis of invasive fungal infection was based on the identification of fungus from a normally sterile site. This positive cultures or microscopy for Aspergillus from a d CMV antibodies Ͼ10 EIU. e Three patients with aplastic anemia were conditioned with cyclophosspecimen taken at bronchoalveolar lavage (BAL) were conphamide only.
sidered cases of probable invasive aspergillosis. Standard microbiological methods for direct microscopy, culture and identification of fungi were used. 12, 13 weeks, then halved approximately at 2-week intervals, and discontinued by day +110) (CsA-MTX-MP). All patients with a matched unrelated donor (MUD) received CsA-MTX-MP prophylaxis. In addition, four out of 11 patients Statistical methods with unrelated donor received antithymocyte globulin (ATG) (20 mg/kg/day for 3 days) as part of their conditionUnivariate comparisons between the groups of patients with and without invasive fungal infection were performed with ing regimen. No T cell-depleted grafts were used.
All patients were cared for in single rooms with HEPA 2 test or with Fisher's test (in case of small cell numbers) for dichotomised variables. In case of three or more classes, filters until recovery from neutropenia (Ͼ1 × 10 9 /l). Antimicrobial prophylaxis included oral acyclovir (1600 the Mantel-Haenzel extension test was used. The distribution of continuous variables was first analyzed with mg/day for 5 weeks) and oral sulfamethoxazole (1600 mg/day) plus trimethoprim (320 mg/day) until recovery Kolmogorov-Smirnov's test and, if found normal, the twotailed Student's t-test for independent samples was used. from neutropenia and three times a week thereafter until 6 months post-BMT. Patients with allergy to sulphonamides Thereafter, variables with a P value Ͻ0.10 after adjustment for age and sex (which were considered putative received intravenous pentamidine during hospitalization and monthly inhalations thereafter. Patients who received determinants) were analyzed with a stepwise forward multiple logistic regression analysis based on the maximuman allograft from a matched unrelated donor received ciprofloxacin 750 twice a day orally or 200 mg twice a day likelihood method. Two final models are shown; one including aGVHD and the other cGVHD (these variables intravenously instead of sulfamethoxazole-trimethoprim until engraftment. All patients received amphotericin B
were not entered simultaneously). P values Ͻ0.05 were considered statistically significant. All the analyses were (AmB) tablets or miconazole gel during the neutropenic period after BMT. No systemic antifungal prophylaxis was performed with the SPSS for WINDOWS program (SPSS Inc, Chicago, IL, USA). given. Systemic antifungal agents, primarily intravenous
Results
( Figure 2 ). Invasive fungal infection was diagnosed in 13 patients after the diagnosis and treatment of aGVHD from 69 to 466 days post-BMT (Aspergillus, 12; Candida, one).
Fungal infections
In five patients (3, 4, 10, 12 and 14 in Table 2 ), IFI was Invasive fungal infection (IFI) was found in 21 of the 142 found after the diagnosis and treatment of extensive BMT patients (15%). In 17 patients (12%) the diagnosis of cGVHD. IFI was definite, whereas in four patients a diagnosis of One hundred and twenty-eight patients (90%) survived probable invasive pulmonary aspergillosis was made on the more than 100 days post-BMT and were thus evaluable for basis of positive culture or microscopy of a specimen taken the development of cGVHD. No signs of cGVHD were at BAL and radiological findings suggestive of fungal observed in 71 patients (55%), limited cGVHD was found infection. Radiological findings included a single pulmonin 34 patients (27%) and extensive cGVHD in 23 patients ary cavity in one patient and multiple focal round lesions (18%). Extensive cGVHD imposed a significant increase in in another. One patient had bilateral pulmonary infiltrates the risk of IFI with an incidence of 39% for late IFIs with rapidly progressive neurological symptoms and mul-(diagnosed Ͼ100 days from BMT) ( Figure 3 ). tiple cerebral lesions on magnetic resonance imaging. The fourth patient had non-specific progressive radiological
Treatment of GVHD and risk of fungal infection findings (chest X-ray/computerized tomography). All these four patients with probable invasive aspergillosis died, but aGVHD was treated in most patients with high-dose autopsy was performed only in one patient after 2 months methylprednisolone (MP) (10 mg/kg/day initially). Thirtyof amphotericin therapy; the diagnosis of Aspergillus infectwo patients received high-dose MP as the only modality tion could not be confirmed.
of GVHD therapy. In addition, three patients were treated Aspergillus sp was the causative agent in 15 patients with smaller doses of MP (1-5 mg/kg/day initially). Invas-(incidence 11%), Candida sp. in four patients (3%), and ive fungal infection was found after high-dose MP in five Fusarium and Absidia each in one patient. The hematologpatients (Aspergillus, 4; Candida, 1) giving an incidence of ical disease, GVHD prophylaxis, severity and treatment of 14% for IFI in this patient group. GVHD as well as the diagnostic findings in patients with ATG was used in 29 patients with aGVHD unresponsive IFI are presented in Table 2 .
to high-dose MP. Twenty-two patients received one 7-10 Fungal infection was diagnosed during life in 17 out of day course of ATG, six patients two courses and one patient 21 patients (81%); four additional patients were found to four courses. IFI was found in 11 patients after the treathave IFI at autopsy. The median time from BMT to the ment with ATG, giving an incidence of 38%. The fungal diagnosis of IFI was 136 days (range 6-466 days). Only infections consisted of 10 cases of Aspergillus infection; three cases of IFI (14%) (Candida, two; Absidia, one) were one patient had Candida infection. diagnosed during the neutropenic period after BMT. The cumulative incidence of IFI was 4% at 3 months, 9% at 6
Analysis of risk factors for fungal infection months, and 14% at 12 months after BMT ( Figure 1 ).
All patients diagnosed to have IFI during life were An attempt was made to analyze possible risk factors for treated with antifungal agents. 19 out of 21 (90%) patients the development of IFI (Table 3 ). In the univariate analysis, with IFI died. The median survival from diagnosis of IFI type of hematological disease (MDS vs other) (P = 0.001), was 28 days (range 5-260 days). In 13 patients (68%), IFI risk category of patients (high-risk vs standard-risk) (P = was considered the main cause of death. Only three patients 0.02), and matched unrelated donor (P = 0.01) were sig-(14%) (Absidia, one; Aspergillus, one; Candida, one) were nificant risk factors. Age, sex, CMV serology, conditioning cured of fungal infection.
regimen or type of GVHD prophylaxis were not associated with the risk of IFI. However, the incidence of IFI tended to be lower in the patients with sibling transplants who GVHD and risk of invasive fungal infections received MTX-CsA-MP prophylaxis than in those who received MTX-CsA prophylaxis (9 vs 16%), although the Two patients (Nos 18 and 21 in Table 2 ) had invasive fungal infections (Candida sepsis, locally invasive Absidia difference did not reach statistical significance. No difference in the mean time to engraftment was infection) diagnosed before day +8. Since aGVHD rarely presents so early after BMT, these patients were excluded observed in the patients who later developed IFI and in those who did not. Of the post-transplant characteristics, from the subsequent analysis of GVHD as a risk factor for IFI.
aGVHD (P = 0.03), cGVHD (P = 0.0002), and treatment of GVHD (P = 0.0001) were risk factors for IFI. The facNo signs of aGVHD were observed in 78 (55%) patients. In this patient group, five patients (6%) had IFI tors with P value Ͻ0.10 were entered in the multiple logistic regression analysis models. However, as the risk cate-(Aspergillus, two; Candida, two; Fusarium, one) diagnosed from 17 to 278 days post-transplant. In three patients (Nos gory of patients is strongly dependent on hematological disease and donor type, it was omitted from the logistic 5, 7 and 8 in Table 2 ), the diagnosis of invasive fungal infection was made after treatment of extensive cGVHD. regression analysis. Similarly, the treatment of GVHD is strongly dependent on the severity of GVHD, and therefore The incidence of grade I-II aGVHD was 28%, and grade III-IV aGVHD was observed in 17% of the patients. The treatment of GVHD was omitted from logistic regression analysis. Odds ratios (OR) with 95% confidence intervals incidence of IFI was 13% in the patients with grade I-II aGVHD but 35% in the patients with grade III-IV aGVHD (CI) adjusted for age and sex are presented in Table 4 . The of acute GVHD. 
Discussion
This single-center analysis of invasive fungal infections type of hematological disease (MDS vs others), donor type (MUD vs sibling), aGVHD (grade III-IV vs 0-II) and after allogeneic BMT with a long follow-up (median 26 months) revealed a clear predominance of late infections cGVHD (extensive vs limited or none) were all statistically significant risk factors for IFI after BMT.
caused by Aspergillus sp. In most patients, the IFIs were associated with post-transplant immunosuppression caused by aGVHD and/or extensive cGVHD as well as their treatment. These observations of the epidemiology of fungal infections and high-risk patients might be of importance especially in finding preventive measures in the BMT setting.
14-16
This analysis involved all adult patients who received allogeneic BMT in the Department of Medicine, Helsinki University Central Hospital between 1989 and 1993. The mean patient age was higher than in previously published reports, partly because of the exclusion of pediatric patients eases, our material is comparable to previous series. A sig- Patients who survived less than 100 days after BMT and patients who had invasive fungal infection diagnosed before day 100 excluded. c Standard-risk patients: AML 1 CR, ALL 1 CR, CML chronic phase/sibling donor. High-risk patients: other disease/disease status/unrelated donor. Frequency (%) in parenthesis.
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Table 4
Age-and sex-adjusted odds ratios (OR) with 95% confidence intervals (CI) for the development of invasive fungal infection in BMT recipients according to multiple logistic regression analysis nificant number of our patients received a corticosteroid as caused by Aspergillus, but is insufficient to prevent late infections. part of their GVHD prophylaxis in addition to MTX-CsA, in contrast to most published reports. Further, we have used Several studies have investigated risk factors for IFI after BMT.
1,3-5 Identified risk factors include recipient CMV a rather aggressive approach to treat established aGVHD, with almost all patients with aGVHD receiving high-dose seropositivity, higher recipient age, prolonged neutropenia after BMT, donor mismatch and aGVHD. We observed no MP initially. A significant number of patients with corticosteroid-resistant aGVHD were treated also with ATG. difference in the mean age or CMV serology of recipients, type of conditioning, GVHD prophylaxis or time to Aspergillus species were responsible for more than two thirds of IFIs in the present study with an incidence of 11% engraftment between the patients with or without IFI. The type of hematological disease (MDS vs other) was for definite or probable Aspergillus infection. In other studies, the incidence of Aspergillus infection has ranged from an important pre-transplant risk factor for the development of IFI in this analysis. In a report by the EBMT, 19 an inci-3 to 7%. 2, 5, 7, 17 There may be at least three explanations for the high incidence of Aspergillus infections observed in this dence of 10% for Aspergillus infection was observed in patients transplanted for secondary leukemia or MDS. In study. First, our study included patients who received their transplants from a matched unrelated donor with a high our series, half of the patients with MDS (5/10) had IFI after BMT. The number of the patients is, however, too incidence (45%) of Aspergillus infection. The rather aggressive post-transplant immunosuppression may also small to draw conclusions and more data are needed. A high incidence of Aspergillus infection (45%) was have been a contributing factor. We also had a long followup after BMT. In view of the late appearance of the Asperfound in the patients with a matched unrelated donor. A previous study has indicated that donor mismatch is a risk gillus infections observed, the true incidence in BMT recipients is critically dependent on the length of the folfactor for IFI. 3 It is possible that despite improving tissue typing techniques, MUD transplants still carry a higher risk low-up.
Invasive Candida infection was observed only in 3% of of IFI than do sibling transplants due to more complex immunobiology. Since the number of BMTs from unrelated the patients, which is probably the lowest incidence reported in allogeneic BMT recipients. In previous studies, donors was small in this series, more data is needed to appreciate the risk of IFI in patients with unrelated donors. the incidence of Candida infections has been 10% or more. [1] [2] [3] [4] With this low incidence observed little efficacy O'Donnell and co-workers 20 observed an increase in the incidence of IFI after introduction of methylprednisolone would be expected from systemic antifungal prophylaxis with activity against yeasts only. Hence, the local epidemias GVHD prophylaxis. In the present material the incidence of IFI was lower (9 vs 16%) in the patients with sibling ological situation is important in determining preventive strategies.
donor who received triple prophylaxis including methylprednisolone when compared to those who received Only 14% of the IFIs in the present material were diagnosed during the neutropenic period post-transplant, in conprophylaxis with MTX-CsA. It is possible that by decreasing the incidence of aGVHD 21 triple prophylaxis may even trast to the data of Morrison and co-workers 7 with more than half of non-Candida fungal infections detected before decrease the morbidity and mortality caused by IFI. Conflicting results have been reported in regard to engraftment. The median time from BMT to the diagnosis of IFI in our study was more than 4 months, considerably aGVHD as a risk factor for IFI. 1, 3, 4, 7, 20 In our patients with grade III-IV aGVHD, the risk of IFI was very high. The longer than in most previous series. 4 
